All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food and Drug Administration, a positive development for what has been a ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older ‌adults, after regulators reversed course on ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

Senior FDA official Vinay Prasad reportedly overrode his staff in deciding to reject Moderna's application for a new seasonal flu shot. Reading time 3 minutes The federal government’s crusade against ...